{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:27:22Z","timestamp":1787761642386,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Carbapenem resistant Enterobacteriacae (CRE) bloodstream infection (BSI) causes complicated infections, especially in immunocompromised patients. This study aimed to assess the renal toxicity and the efficacy of therapy with colistin in a cohort of pediatric cancer patients with BSIs due to CRE and sensitivity to colistin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>This was an observational, prospective cohort study from May 2017 to October 2017 in Children's Cancer Hospital Egypt 57,357. All patients who had blood stream infections due to CRE receiving intravenous colistin were prospectively enrolled. We used a standardized case form to record patient characteristics, including age, sex, weight, underlying comorbidities, type of infection, causative organism, and antibiotic susceptibility testing. Daily doses, duration of colistin therapy, and co-administered antibiotics (aminoglycosides, vancomycin) were collected. Furthermore, clinical and microbiological responses to treatment were reported. The dosing schedule was based on a loading dose of 5 MU and a 5-MU twice-daily divided maintenance dose, titrated on renal function. Clinical cure, bacteriological clearance, and daily serum creatinine were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      One hundred and forty-one Blood Stream infectious episodes mainly due to Klebsiella Species (pneumoniae and Oxytoca) (27%) and\n                      <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                      (68%) were analyzed. All strains were susceptible to colistin with Minimum inhibitory concentration (MICs) of 0.19\u20131.5 mg\/L. Patients were predominantly females (69%), with a mean age of 7 years. It was used as a combination therapy with carbapenems (69.2%) or aminoglycosides (80%). The median duration of treatment was 9 days (Range 1\u201350 days). Clinical and microbiological cure was observed in 110 cases (80%). Acute kidney injury developed during five treatment courses (4%) in which colistin was used in combination with amikacin. No renal replacement therapy was required and subsided within 7 days from colistin discontinuation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our study showed that colistin had a high efficacy without significant renal toxicity in severe infections due to CRE Gram-negative bacteria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aam.aam_209_21","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T06:13:35Z","timestamp":1682057615000},"page":"82-87","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Outcome and Safety of Colistin Usage in Pediatric Cancer Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia at Children Cancer Hospital Egypt"],"prefix":"10.4103","volume":"22","author":[{"given":"Nagla","family":"Adel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reham","family":"Khedr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervat","family":"Elanany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala F.","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanafy","family":"Hafez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"El-Abhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20240831","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.bjid.2014.05.012","article-title":"Predictors of 7- and 30-day mortality in pediatric intensive care unit patients with cancer and hematologic malignancy infected with gram-negative bacteria","volume":"18","author":"Costa Pde","year":"2014","journal-title":"Braz J Infect Dis"},{"key":"R2-13-20240831","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2046-4053-1-8","article-title":"Predicting infectious complications in neutropenic children and young people with cancer (IPD protocol)","volume":"1","author":"Phillips","year":"2012","journal-title":"Syst Rev"},{"key":"R3-13-20240831","first-page":"1803","article-title":"Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: Retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R4-13-20240831","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jinf.2014.05.018","article-title":"Bloodstream infections in neutropenic patients with cancer: Differences between patients with haematological malignancies and solid tumours","volume":"69","author":"Marin","year":"2014","journal-title":"J Infect"},{"key":"R5-13-20240831","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4137\/PMC.S14459","article-title":"Antibiotics and bacterial resistance in the 21st century","volume":"6","author":"Fair","year":"2014","journal-title":"Perspect Medicin Chem"},{"key":"R6-13-20240831","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4103\/0022-3859.118040","article-title":"Colistin: Re-emergence of the \u2018forgotten\u2019 antimicrobial agent","volume":"59","author":"Dhariwal","year":"2013","journal-title":"J Postgrad Med"},{"key":"R7-13-20240831","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1056\/NEJM196204122661505","article-title":"Neurotoxic and nephrotoxic effects of colistin in patients with renal disease","volume":"266","author":"Wolinsky","year":"1962","journal-title":"N Engl J Med"},{"key":"R8-13-20240831","first-page":"24","article-title":"Antibiotic activity of Bacillus polymyxa","volume":"54","author":"Benedict","year":"1947","journal-title":"J Bacteriol"},{"key":"R9-13-20240831","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/cid\/cir611","article-title":"Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system","volume":"53","author":"Pogue","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R10-13-20240831","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/cid\/ciu069","article-title":"Treatment of multidrug-resistant Gram-negative infections in children","volume":"58","author":"Hsu","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R11-13-20240831","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R12-13-20240831","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting","volume":"36","author":"Horan","year":"2008","journal-title":"Am J Infect Control"},{"key":"R13-13-20240831","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1086\/528867","article-title":"Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram-negative bacilli: Need for international harmonization in terminology","volume":"46","author":"Falagas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R14-13-20240831","doi-asserted-by":"crossref","first-page":"42","DOI":"10.7748\/ns.24.42.42.s49","article-title":"Best practice in the measurement of bodytemperature","volume":"24","author":"Davie","year":"2010","journal-title":"Nursing Standard (Royal College of Nursing (GreatBritain): 1987"},{"key":"R15-13-20240831","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1365-2141.2011.08693.x","article-title":"Improving the immediate management ofneutropenic sepsis in the UK: lessons from a national audit","volume":"153","author":"Clarke","year":"2011","journal-title":"British Journal of Haematology"},{"key":"R16-13-20240831","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12427","article-title":"ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant gram-negative bacteria in hospitalized patients","volume":"20","author":"Tacconelli","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R17-13-20240831","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1442-200X.2009.03015.x","article-title":"Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients","volume":"52","author":"Celebi","year":"2010","journal-title":"Pediatr Int"},{"key":"R18-13-20240831","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0031-3955(16)36251-4","article-title":"The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents","volume":"34","author":"Schwartz","year":"1987","journal-title":"Pediatr Clin North Am"},{"key":"R20-13-20240831","doi-asserted-by":"crossref","first-page":"N64","DOI":"10.1097\/00003246-200104001-00002","article-title":"Increasing prevalence of antimicrobial resistance in intensive care units","volume":"29","author":"Fridkin","year":"2001","journal-title":"Crit Care Med"},{"key":"R21-13-20240831","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/INF.0b013e31818a5dbd","article-title":"Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis","volume":"28","author":"Falagas","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R22-13-20240831","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/BCR.0B013E318053D346","article-title":"Intravenous colistin for the treatment of multi-drug resistant, gram-negative infection in the pediatric burn population","volume":"28","author":"Goverman","year":"2007","journal-title":"J Burn Care Res"},{"key":"R23-13-20240831","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1097\/PCC.0b013e31828a740f","article-title":"Intravenous colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients","volume":"14","author":"Kapoor","year":"2013","journal-title":"Pediatr Crit Care Med"},{"key":"R24-13-20240831","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4103\/0972-5229.45074","article-title":"Safety and efficacy of polymyxin B in multidrug resistant gram-negative severe sepsis and septic shock","volume":"12","author":"Ramasubban","year":"2008","journal-title":"Indian J Crit Care Med"},{"key":"R25-13-20240831","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ajic.2016.08.008","article-title":"Predictors of mortality in bloodstream infections caused by multidrug-resistant gram-negative bacteria: 4 years of collection","volume":"45","author":"Wang","year":"2017","journal-title":"Am J Infect Control"},{"key":"R26-13-20240831","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-72-6-857","article-title":"Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy","volume":"72","author":"Koch-Weser","year":"1970","journal-title":"Ann Intern Med"},{"key":"R28-13-20240831","first-page":"301","article-title":"Monitoring of effectiveness and safety of colistin for therapy in resistant gram-negative bacterial infections in hospitalized patients at siriraj hospital","volume":"99","author":"Thamlikitkul","year":"2016","journal-title":"J Med Assoc Thai"},{"key":"R29-13-20240831","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1086\/599225","article-title":"Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center","volume":"48","author":"Hartzell","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R30-13-20240831","doi-asserted-by":"crossref","first-page":"318","DOI":"10.7883\/yoken.JJID.2014.223","article-title":"Incidence and risk factors for colistin-associated nephrotoxicity","volume":"68","author":"Temocin","year":"2015","journal-title":"Jpn J Infect Dis"}],"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_209_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:02:43Z","timestamp":1787760163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_209_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/aam.aam_209_21","relation":{},"ISSN":["1596-3519"],"issn-type":[{"value":"1596-3519","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}